Teva Continues Divestitures To Close Allergan Deal With Sale To Impax

Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.

capsules

Teva Pharmaceutical Industries Ltd. will offload 15 generic drug products and a host of pipeline opportunities to Impax Laboratories Inc. for $586m; the divestiture is part of an ongoing process to meet Federal Trade Commission antitrust requirements related to its pending acquisition of Allergan PLC's generics business, and follows other previously announced deals.

Impax said on June 21 that the new products will be immediately accretive to the generics specialist's 2016 bottom line...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip